The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. Not only is this morally right but it is also the fastest way to end the pandemic. So as world leaders line up to make deals for COVID-19 vaccines candidates we want to know: did this deal move us closer to, or further from, an equitable outcome?

The Vaccine Access Test provides a framework to answer this question by evaluating deals between companies and countries using three metrics:

➔ **Prioritized**: Is this deal aligned with global guidelines on prioritizing allocation among at-risk populations?

➔ **Phased**: Does this deal allow for phased delivery of doses to ensure initial-supply is not monopolized?

➔ **Published**: Is the contracting process transparent from start to finish?

Each metric is worth up to 2 points with the potential for 6 points total. Here is how this deal stacks up.

### DEAL SUMMARY

**Parties**: Moderna and the United Kingdom

**Date**: November 17, 2020

**Terms of Agreement**: The U.K. announced an initial agreement with Moderna for five million doses of mRNA-1273, its COVID-19 vaccine candidate, beginning in March 2021. Financial terms of the deal were not disclosed.

<table>
<thead>
<tr>
<th>METRIC</th>
<th>SCORE</th>
<th>RATIONALE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prioritized</td>
<td>1.5</td>
<td>5m doses would cover just over 3.8% of the United Kingdom's population with a 2-dose regimen, exceeding the 3% initial allocation threshold but more closely in line with prioritising frontline health and social care workers in the UK than previous bilateral deals and within the threshold to prioritize the most vulnerable 20% population.</td>
</tr>
<tr>
<td>Phased</td>
<td>0</td>
<td>The deal does not include phased delivery of doses nor the option to obtain additional doses later. Ideally, deals would allow for other countries to benefit from the initial supply and tier delivery of subsequent supply as it becomes available.</td>
</tr>
<tr>
<td>Published</td>
<td>0</td>
<td>The United Kingdom has not listed details about the terms of deal and pricing online. Moderna have not disclosed their pricing model.</td>
</tr>
</tbody>
</table>

**Total Score: 1.5 out of 6**

Compared to other deals announced by the UK government to date this deal more closely aligns with the global population allocation guidelines, thus enabling other countries to have access to limited supply.

The UK government should publish details of the deal and Moderna should disclose a break-down of how they arrived at their unit price, and what it costs to produce the vaccine. We will also be watching to ensure subsequent doses aren't purchased before other countries have secured deals for portions of the initial supply.

Check out the full methodology and scores for other deals, countries, and companies at ONE.org/VaccineAccessTest
Check out the full methodology and scores for other deals, countries, and companies at ONE.org/VaccineAccessTest